^
    Back
    Association details:
    Biomarker:MET amplification
    Cancer:Gastric Cancer
    Drug:Orpathys (savolitinib) (c-MET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Savolitinib for Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients

    Excerpt:
    ...MET gene amplifications 5....
    Trial ID:
    NCT04923932
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

    Excerpt:
    ...Patients with MET amplification....
    Trial ID:
    NCT02449551
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment

    Excerpt:
    ...- Although it is preferred to enroll patients with solid tumors harboring MET amplification, this will...
    Trial ID:
    NCT02447406
    Less C2 evidence
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncologist
    Title:

    Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Efficacy, and Biomarkers

    Published date:
    04/21/2022
    Excerpt:
    Notably, in gastric cancer, response was only observed in patients with MET amplification (copy number 9.7-18.4), with an objective response rate of 35.7% and a disease control rate of 64.3%...The RP2D of savolitinib was established as 600 mg QD or 500 mg BID in Chinese patients. The promising response observed in patients with gastric cancer with c-met amplification...
    DOI:
    10.1093/oncolo/oyab066
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Matched therapies for advanced gastric cancer based on genotype: A real-world study in China.

    Published date:
    05/19/2021
    Excerpt:
    ...11 (37%) harbored c-MET amplification/overexpression (received savolitinib or crizotinib, cohort A)....three of 11 patients had an objective response (1 complete response and 2 partial responses, objective response rate (ORR) 27%), disease control rate (DCR) was 45%, median progression-free survival (mPFS) was 2.1 months, and median overall survival (mOS) was 3.7 months.
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial

    Published date:
    07/17/2019
    Excerpt:
    Circulating tumor (ctDNA) analysis demonstrated good correlation between high MET copy number by ctDNA and response to savolitinib.
    DOI:
    10.1158/2159-8290.CD-19-0442